Study finds, approximately one-third of the hospitalised Covid 19 patients develop brain malfunctions

COVID 19 patients

It is already in News that COVID 19 disease is much more than just a respiratory illness and now, the new research sheds light on how it affects another important part of our body, i.e, the brain.

Nearly one-third of the patients hospitalized due to COVID 19 disease developed an encephalopathy, which means degeneration of brain function, a study by Northwestern Medicine in Chicago revealed.

A recent study concern over President stay at the hospital

The research findings raise a serious concern over President Donald Trump knowing that he has stayed three nights at Walter Reed Medical Center and on a big picture it also highlights the mental damage the Coronavirus imposed on the tens of thousands of Americans.

According to the data provided by the COVID tracking project, more than 4,15,000 people have been hospitalized in the United States of America due to this disease and the disease has killed nearly 2,10,000 people and approximately 7.5 million Americans are infected by the virus.

What is Encephalopathy?

Dr. Igor Koralnik, a professor of neurology at Northwestern University who treats patients in the Northwestern Medicine healthcare describes Encephalopathy as it is characterized by altered mental function ranging from mild confusion to coma and is the most severe neurologic manifestation of COVID-19.

Koralnik is also among the authors of the study and the first one of its kind in the US, who conducted research on 509 COVID 19 patients with the hospital network in Chicago.

What does the research say?

The research was published on Monday in the Annals of Clinical and Translational Neurology and it explored the neurologic manifestations of the COVID 19 virus. It also found that some neurologic manifestations were present in 82.3 % of the patients at some point during the course of the disease.

The symptoms included are muscle pain (44.8% of all those reviewed), headaches (37.7%), encephalopathy (31.8%), dizziness (29.7%), and disorders of taste (15.9%) and smell (11.4%).

The study is applicable to all the nationals

Dr. Richard Temes, director of the Center for Neurocritical Care at Northwell Health in Manhasset, New York, said that although the study examined in the area of Chicago these are applicable nationally because COVID 19 virus doesn’t care for boundaries, borders, or geography.

He said that the researchers noted down that most people infected with the virus won’t develop harsh symptoms but those who are critically ill, which means required to stay in ICU and possibly fainted and use of ventilator are at higher risk of these manifestations.

He further added that this study is for the survivors of the COVID 19, their recovery is just a beginning. The disease can have long-lasting and lethargic effects.

 

Also read: HC stays Delhi government decision to reserve 80% ICU beds in 33 private hospitals for Covid-19 patients